Allink Biotherapeutics, a clinical-stage biotechnology company specializing in next-generation bispecific antibody and antibody-drug conjugate (ADC) therapeutics, has announced the successful completion of a $42 million Series A financing round. Led by Lanchi Ventures, the funding will accelerate the global development of AllinkBio's pipeline and expand its clinical programs.
Investment Details and Strategic Goals
The Series A round saw participation from new investors including Yuanbio Venture Capital, Legend Capital, and C&D Emerging Industry Equity Investment, alongside continued support from existing shareholders Gaorong Ventures and Med-Fine Capital. The proceeds will be strategically allocated to several key areas:
- Advancing the global clinical development of lead candidates ALK201 and ALK202 through Phase 1 studies in Australia, the United States, and China.
- Enriching the current portfolio by developing multiple new assets in oncology and immunology.
- Further developing the company’s proprietary bispecific antibody and ADC technology platform.
- Expanding the company’s global footprint.
Leadership Perspective
Hui Feng, Ph.D., Founder and Chief Executive Officer of AllinkBio, stated, “Since company inception a little over a year ago, AllinkBio has rapidly advanced from lead asset PCC to clinical development stage. We are grateful for the continued support from existing shareholders and delighted to welcome new investors who recognize both our scientific excellence and capability of translating scientific findings into clinical applications. Their support enables us to accelerate the development of our diverse pipeline spanning multiple modalities including next-generation ADCs and bispecific antibodies targeting oncology and immunology diseases. Looking ahead, we are poised to achieve multiple pipeline milestones in the coming months as we pursue our long-term mission of bringing innovative therapeutics to patients with significant unmet medical needs.”
Industry Commentary
Lanchi Ventures commented on AllinkBio's progress, stating, “AllinkBio’s exceptional execution speed and quality in advancing its lead program from preclinical to clinical stage, led by Dr. Feng, one of the leading figures in China’s biopharmaceutical industry, demonstrates the company’s high competitiveness in the field. AllinkBio’s innovative approach to ADC development presents a compelling opportunity in the targeted oncology therapeutics space.”
About Allink Biotherapeutics
Founded in 2023, AllinkBio is focused on developing First-in-Class (FIC) and Best-in-Class (BIC) therapeutics using its proprietary platforms in bispecific antibodies and ADCs. The company aims to address critical unmet medical needs in oncology and immunology.
